Optimer to file fidaxomicin after second positive Phase III study
This article was originally published in Scrip
Optimer Pharmaceuticals' narrow-spectrum antibiotic fidaxomicin has met the non-inferiority primary endpoint of its second Phase III study for the treatment of Clostridium difficile infections.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.